{
  "question_stem": {
    "en": "A 23-year-old man is evaluated for excessive bruising since childhood. He says some of his family members \"bleed easily\" and sometimes require blood transfusions. Temperature is 36.7 C (98.1 F). Physical examination is unremarkable. Complete blood cell count is unremarkable. Platelet aggregometry is abnormal. Genetic testing identifies a defect in a platelet surface glycoprotein receptor that normally binds fibrinogen to support platelet aggregation.",
    "zh": "一名23岁男性因自幼以来出现过度瘀伤而接受评估。他说他的一些家庭成员“容易出血”，有时需要输血。体温36.7摄氏度（98.1华氏度）。体格检查无特殊发现。全血细胞计数无特殊发现。血小板聚集试验异常。基因检测发现血小板表面糖蛋白受体存在缺陷，该受体通常与纤维蛋白原结合以支持血小板聚集。"
  },
  "question": {
    "en": "The abnormal glycoprotein receptor found in this patient is most likely targeted by which of the following medications?",
    "zh": "在该患者身上发现的异常糖蛋白受体最有可能被以下哪种药物靶向？"
  },
  "options": {
    "A": {
      "en": "Abciximab",
      "zh": "阿昔单抗"
    },
    "B": {
      "en": "Argatroban",
      "zh": "阿加曲班"
    },
    "C": {
      "en": "Aspirin",
      "zh": "阿司匹林"
    },
    "D": {
      "en": "Clopidogrel",
      "zh": "氯吡格雷"
    },
    "E": {
      "en": "Dabigatran",
      "zh": "达比加群酯"
    },
    "F": {
      "en": "Heparin",
      "zh": "肝素"
    },
    "G": {
      "en": "Warfarin",
      "zh": "华法林"
    }
  },
  "correct_answer": "A",
  "explanation": {
    "en": "This patient likely has GLANZMANN THROMBASTHENIA, an autosomal recessive disorder that is caused by a deficient or defective glycoprotein (GP) IIb/IIIa on platelet surfaces and that typically presents in childhood with mucocutaneous bleeding. Peripheral smear shows no platelet clumping (an important clue for diagnosis). \n\nPlatelets are responsible for formation of platelet plugs that stop bleeding from injured vessels (primary hemostasis). Vessel wall injury exposes the subendothelial collagen and matrix. Platelet attachment to exposed collagen is strengthened by GP Ib binding to von Willebrand factor on the vessel wall. The resulting platelet activation leads to the following:\n\n•\tRelease of mediators (eg, ADP, thromboxane A2 [TXA2]) into circulation, which in turn activates other platelets\n•\tConformational structural change of GP IIb/IIIa on platelet surfaces; this allows thousands of copies of GP IIb/IIIa to bind fibrinogen, thereby forming a platelet plug. {{exhibit_1}}\n\nAbciximab, a GP IIb/IIIa receptor antagonist, inhibits binding of this receptor to fibrinogen. Abciximab and other GP IIb/IIIa inhibitors are useful for treatment of unstable angina and acute coronary syndrome, particularly in patients undergoing percutaneous coronary intervention.\n\n(Choices B, E, F, and G) Argatroban (used in heparin-induced thrombocytopenia) and dabigatran (used in atrial fibrillation or venous thromboembolism) are direct thrombin inhibitors. Heparin potentiates antithrombin III activity, leading to inactivation of thrombin and factor Xa; warfarin prevents K-mediated carboxylation of several coagulation factors. All these medications have anticoagulant effects.\n\n(Choices C and D) Aspirin, a cyclooxygenase (COX)-1 and 2 inhibitor, inhibits TXA2 (via platelet COX acetylation), thereby preventing platelet aggregation. Clopidogrel inhibits platelet aggregation by blocking P2Y12 on platelet ADP receptors. {{exhibit_2}}",
    "zh": "该患者可能患有格拉斯曼血小板无力症，这是一种常染色体隐性遗传疾病，由血小板表面的糖蛋白（GP）IIb/IIIa 缺陷或功能障碍引起，通常在儿童时期表现为皮肤黏膜出血。外周血涂片显示无血小板凝集（这是诊断的重要线索）。\n\n血小板负责形成血小板栓子，以阻止受损血管的出血（一级止血）。血管壁损伤会暴露内皮下胶原和基质。血小板与暴露的胶原的附着通过GP Ib与血管壁上的血管性血友病因子结合而加强。由此产生的血小板活化会导致以下情况：\n\n•\t释放介质（例如，ADP、血栓烷A2 [TXA2]）到循环中，进而激活其他血小板\n•\t血小板表面GP IIb/IIIa的构象结构变化；这使得成千上万个GP IIb/IIIa拷贝能够与纤维蛋白原结合，从而形成血小板栓子。 {{exhibit_1}}\n\n阿昔单抗是一种GP IIb/IIIa受体拮抗剂，可抑制该受体与纤维蛋白原的结合。阿昔单抗和其他GP IIb/IIIa抑制剂可用于治疗不稳定型心绞痛和急性冠脉综合征，特别是在接受经皮冠状动脉介入治疗的患者中。\n\n（选项B、E、F和G）阿加曲班（用于肝素诱导的血小板减少症）和达比加群酯（用于心房颤动或静脉血栓栓塞）是直接凝血酶抑制剂。肝素增强抗凝血酶III的活性，导致凝血酶和因子Xa失活；华法林阻止K介导的几种凝血因子的羧化。所有这些药物都具有抗凝作用。\n\n（选项C和D）阿司匹林，一种环氧合酶（COX）-1和2抑制剂，通过血小板COX乙酰化抑制TXA2，从而阻止血小板聚集。氯吡格雷通过阻断血小板ADP受体上的P2Y12来抑制血小板聚集。 {{exhibit_2}}"
  },
  "summary": {
    "en": "This question tests knowledge of Glanzmann thrombasthenia, a platelet disorder, and the mechanism of action of abciximab, a glycoprotein IIb/IIIa receptor antagonist. It also requires understanding of primary hemostasis and platelet plug formation.\n\nTo solve this question, recognize the clinical presentation of Glanzmann thrombasthenia (childhood bleeding, abnormal platelet aggregation) and identify the glycoprotein IIb/IIIa receptor as the target. Then, select the medication that specifically inhibits this receptor.",
    "zh": "这道题测试对格拉斯曼血小板无力症（一种血小板疾病）的了解以及阿昔单抗（一种糖蛋白IIb/IIIa受体拮抗剂）的作用机制。它还需要理解一级止血和血小板栓子形成。\n\n要解决这个问题，需要识别格拉斯曼血小板无力症的临床表现（儿童出血、血小板聚集异常），并将糖蛋白IIb/IIIa受体确定为靶标。然后，选择专门抑制该受体的药物。"
  },
  "tags": "Glanzmann thrombasthenia; Platelet aggregation; Glycoprotein IIb/IIIa; Abciximab; Primary hemostasis; Hematology; Platelet disorders; Bleeding disorders",
  "category": "Blood",
  "question_id": "1079",
  "has_exhibits": true,
  "exhibit_count": 2,
  "exhibit_files": [
    "image1.jpg",
    "image2.jpg"
  ],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\Blood 23\\1079",
  "extracted_at": "2025-11-05T11:18:52.418035",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 1,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T16:25:29.690072",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}